MRK | Weekly | Haru Insights

The FDA approval of LIPFENDRA (enlicitide), the first oral PCSK9 inhibitor, marks a transformative milestone for Merck, establishing the company as a leader in cardiometabolic innovation and opening a high-growth therapeutic pathway with significant commercial potential.
The positive Phase 3 INTerpath-001 readout for intismeran autogene plus KEYTRUDA in resected melanoma delivers the first-ever successful Phase 3 trial for an individualized mRNA cancer therapy, fundamentally validating Merck’s shift from Keytruda-dependent legacy player to a true innovator in personalized immuno-oncology.

Merck has decisively positioned itself at the forefront of next-generation oncology with a breakthrough in personalized mRNA therapy, signaling a powerful evolution beyond traditional immunotherapy and reinforcing long-term growth credibility.
The launch of LIPFENDRA as the first oral PCSK9 inhibitor represents a paradigm shift in cardiovascular care, offering unmatched patient convenience and establishing Merck as a strategic disruptor in a high-value, underserved market segment.
The success of intismeran autogene in Phase 3 proves the clinical viability of Merck’s mRNA platform, turning theoretical promise into tangible validation and validating years of R&D investment.
With two landmark approvals in one week—one in cardiology, one in oncology—Merck demonstrates rare breadth and depth in innovation, dramatically strengthening its pipeline credibility.
The FDA nod for LIPFENDRA elevates Merck’s profile beyond Keytruda, creating a new revenue anchor with high margins and strong patient adherence potential due to oral administration.

Merck & Co., Inc. (MRK)[Tv]